UNITED STATES

0001548123-12-000319.txt : 20121029 0001548123-12-000319.hdr.sgml : 20121029 20121026183208 ACCESSION NUMBER: 0001548123-12-000319 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121029 DATE AS OF CHANGE: 20121026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANCER CAPITAL CORP CENTRAL INDEX KEY: 0001130889 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 911803648 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32363 FILM NUMBER: 121165403 BUSINESS ADDRESS: STREET 1: 2157 S. LINCOLN STREET 2: 2157 S. LINCOLN CITY: SALT LAKE CITY STATE: UT ZIP: 84106 BUSINESS PHONE: 8013232395 MAIL ADDRESS: STREET 1: 2157 S. LINCOLN STREET 2: 2157 S. LINCOLN CITY: SALT LAKE CITY STATE: UT ZIP: 84106 10-Q 1 ccap_12q31.htm QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2012 UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number: 000-32363

CANCER CAPITAL CORP.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

91-1803648

(I.R.S. Employer Identification No.)

2157 S. Lincoln Street, Salt Lake City, Utah

(Address of principal executive offices)

84106

(Zip code)

(801) 323-2395

(Registrant’s telephone number, including area code)

The registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ] The registrant does not have a Web site.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]

Non-accelerated filer [ ]

Accelerated filer [ ]

Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [X] No [ ]

The number of shares outstanding of the registrant’s common stock as of October 25, 2012 was 6,150,000.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Balance Sheets

Condensed Statements of Operations

Condensed Statements of Cash Flows

Condensed Notes to the Financial Statements

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Item 4. Controls and Procedures

PART II – OTHER INFORMATION

Item 6. Exhibits

Signatures

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CANCER CAPITAL CORP.

(A Development Stage Company)

Financial Statements

September 30, 2012

Cancer Capital Corp.

(A Development Stage Company)

Condensed Balance Sheets



		SEPT 30, 2012		DEC 31, 2011
		(Unaudited)

ASSETS
CURRENT ASSETS
Cash	$	2,705	$	161
Total current assets		2,705		161
Total assets	$	2,705	$	161

LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable - related party	$	43,725	$	28,250
Accounts payable		54,306		44,156
Total current liabilities		98,031		72,406
Total liabilities		98,031		72,406

STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding		6,150		6,150
Additional paid-in capital		47,050		47,050
Deficit accumulated during the development stage		(148,526)		(125,445)
Total stockholders' deficit		(95,326)		(72,245)
Total liabilities and stockholders' deficit	$	2,705	$	161

The accompany notes are an integral part of these financial statements

Cancer Capital Corp.

(Development Stage Company)

Condensed Statements of Operations

(Unaudited)



		FOR THREE MONTHS ENDED SEPT 30, 2012		FOR THREE MONTHS ENDED SEPT 30, 2011		FOR NINE MONTHS ENDED SEPT 30, 2012		FOR NINE MONTHS ENDED SEPT 30, 2011		FROM INCEPTION ON APR 11, 1997 TO SEPT 30, 2012

Revenues	$	0	$	0	$	0	$	0	$	0

Expenses
General and administrative		6,369		1,451		23,081		5,935		148,526
Total expenses		6,369		1,451		23,081		5,935		148,526

Loss from operations before income taxes		(6,369)		(1,451)		(23,081)		(5,935)		(148,526)

Taxes		0		0		0		0		0

Net loss	$	(6,369)	$	(1,451)	$	(23,081)	$	(5,935)	$	(148,526)

Net loss per share	$	(0.00)	$	(0.00)	$	(0.00)	$	(0.00)

Weighted average shares outstanding		6,150,000		6,150,000		6,150,000		6,150,000

The accompany notes are an integral part of these financial statements

Cancer Capital Corp.

(A Development Stage Company)

Condensed Statements of Cash Flows

(Unaudited)



		FOR NINE MONTHS ENDED SEPT 30, 2012		FOR NINE MONTHS ENDED SEPT 30, 2011		FROM INCEPTION ON APR 11, 1997 TO SEPT 30, 2012

Cash Flows from Operating Activities
Net Loss	$	(23,081)	$	(5,935)	$	(148,526)
Adjustment to reconcile net loss to cash provided (used) by operating activities:
Common stock issued for services rendered		0		0		17,200
Changes in assets and liabilities:
Increase in accounts payable and accrued expenses		25,625		4,825		98,031
Net cash provided (used) by operating activities		2,544		(1,110)		(33,295)

Cash Flows from Investing Activities
Net cash provided by investing activities		0		0		0

Cash Flows from Financing Activities
Common stock issued for cash		0		0		36,000
Net cash provided by financing activities		0		0		36,000

Increase (decrease) in cash		2,544		(1,110)		2,705

Cash and cash equivalents at beginning of period		161		2,007		0

Cash and cash equivalents at end of period	$	2,705	$	897	$	2,705

Supplemental Cash Flow Information:
Cash paid for interest	$	0	$	0	$	0
Cash paid for income taxes	$	0	$	0	$	0

Non-Cash Investing and Financing Activities
Stock issued for services	$	0	$	0	$	17,200

The accompany notes are an integral part of these financial statements

Cancer Capital Corp.

(A Development Stage Company)

Notes to the Unaudited Condensed Financial Statements

September 30, 2012

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2011 Annual Report on Form 10-K. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for year ending December 31, 2012.

NOTE 2 – Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

NOTE 3 – Subsequent Events

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

In this report references to “Cancer Capital,” “the Company,” “we,” “us,” and “our” refer to Cancer Capital Corp.

FORWARD LOOKING STATEMENTS

The Securities and Exchange Commission (“SEC”) encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “intend,” “expect,” “believe,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Executive Overview

We are a development stage company and have not recorded revenues for the past two fiscal years. At September 30, 2012 we had cash of $2,705 and total liabilities of $98,031. We are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may effect a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

Management anticipates that the struggling global economy will restrict the number of business opportunities available to us and will restrict the cash available for such transactions. There can be no assurance in the current economy that we will be able to acquire an interest in an operating company.

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

Liquidity and Capital Resources

We have not recorded revenues from operations since inception. We have not established an ongoing source of revenue sufficient to cover our operating costs and we have relied primarily upon related parties to provide and pay for professional and operational expenses. At September 30, 2012 we had $2,705 cash compared to $161 cash at December 31, 2011 and the increase is primarily related to cash advances from related parties. At September 30, 2012 total liabilities increased to $98,031 compared to $72,406 at December 31, 2011. This increase represents $25,625 accounts payable for cash advances, consulting services and professional services provided by or paid for by a related party.

We intend to obtain capital from management, significant stockholders and/or third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through funds provided by management, significant stockholders and/or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.

Results of Operations

We did not record revenues in either of the three or nine month periods ended September 30, 2011 or 2012. General and administrative expense increased from $1,451 for the 2011 third quarter to $6,369 for the 2012 third quarter and general and administrative expense increased from $5,935 for the 2011 nine month period compared to $23,081 for 2012 nine month period. The increases in general and administrative expense in the 2012 interim periods primarily reflect increased costs for professional and consulting services relied upon for our operations.

Accordingly, our net loss increased from $1,451 for the 2011 third quarter to $6,369 for the 2012 third quarter and our net loss increased from $5,935 for the 2011 nine month period compared to $23,081 for the 2012 nine month period. Management expects net losses to continue until we acquire or merge with a business opportunity.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were ineffective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

Changes to Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended September 30, 2012 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 6. EXHIBITS

Part I Exhibits


No.	Description
31.1	Principal Executive Officer Certification
31.2	Principal Financial Officer Certification
32.1	Section 1350 Certification

Part II Exhibits


No.	Description
3(i)	Articles of Incorporation (Incorporated by reference to exhibit 3.1 of Form 10-SB, File No. 000-32363, filed February 20, 2001)
3(ii)	Bylaws of Cancer Capital (Incorporated by reference to exhibit 3.2 of Form 10-SB, File No. 000-32363, filed February 20, 2001)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.CAL	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Label Linkbase Document

Part II Exhibits - continued


No.	Description
101.PRE	XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 26, 2012

CANCER CAPITAL CORP.

By: /s/John W. Peters

John W. Peters

President and Director

Principal Financial Officer

EX-31 2 ex311.htm PRINCIPAL EXECUTIVE OFFICER CERTIFICATION Exhibit 31

Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

I, John W. Peters, certify that:

I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2012

/s/ John W. Peters

John W. Peters

Principal Executive Officer

EX-31 3 ex312.htm PRINCIPAL FINANCIAL OFFICER CERTIFICATION Exhibit 31

Exhibit 31.2

PRINCIPAL FINANCIAL OFFICER CERTIFICATION

I, John W. Peters, certify that:

I have reviewed this quarterly report on Form 10-Q of Cancer Capital Corp.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2012

/s/ John W. Peters

John W. Peters

Principal Financial Officer

EX-32 4 ex32.htm SECTION 1350 CERTICATION Exhibit 32

Exhibit 32.1

CANCER CAPITAL CORP.

CERTIFICATION OF PERIODIC REPORT

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

18 U.S.C. Section 1350

The undersigned executive officer of Cancer Capital Corp. certifies pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

the quarterly report on Form 10-Q of Cancer Capital Corp. for the quarter ended September 30, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cancer Capital Corp.

Date: October 26, 2012

/s/ John W. Peters

John W. Peters

Principal Executive Officer

Principal Financial Officer

EX-101.INS 5 cncl-20120930.xml XBRL INSTANCE DOCUMENT 10-Q 2012-09-30 false CANCER CAPITAL CORP 0001130889 --12-31 Smaller Reporting Company Yes No No 2012 Q3

6369

1451

23081

5935

148526

6369

1451

23081

5935

148526

-6369

-1451

-23081

-5935

-148526

-6369

-1451

-0.00

6150000

-23081

-5935

-148526

25625

4825

98031

2544

-1110

-33295

36000

2544

-1110

2705

2007

897

2705

17200

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION     The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements.  Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Companys audited financial statements and notes thereto included in its December 31, 2011 Annual Report on Form 10-K.  Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for year ending December 31, 2012.   NOTE 2 Going Concern   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities.  Its activities have been limited for the past several years and it is dependent upon financing to continue operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.  It is managements plan to acquire or merge with other operating companies.

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION     The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements.  Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Companys audited financial statements and notes thereto included in its December 31, 2011 Annual Report on Form 10-K.  Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for year ending December 31, 2012.

NOTE 2 Going Concern   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities.  Its activities have been limited for the past several years and it is dependent upon financing to continue operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.  It is managements plan to acquire or merge with other operating companies.

0.001

20000000

6150000

NOTE 3 Subsequent Events   The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

2705

161

2705

161

2705

161

43725

28250

54306

44156

98031

72406

98031

72406

6150

47050

148526

125445

-95326

-72245

2705

161

6150000 0001130889 2012-01-01 2012-09-30 0001130889 2012-09-30 0001130889 2011-12-31 0001130889 2012-07-01 2012-09-30 0001130889 2011-07-01 2011-09-30 0001130889 2011-01-01 2011-09-30 0001130889 1997-04-11 2012-09-30 0001130889 2010-12-31 0001130889 1997-04-10 0001130889 2011-09-30 0001130889 2012-10-25 shares iso4217:USD iso4217:USD shares EX-101.PRE 6 cncl-20120930_pre.xml XBRL TAXONOMY PRESENTATION LINKBASE DOCUMENT EX-101.LAB 7 cncl-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cash Flows from Operating Activities Total current liabilities Total current liabilities Document Fiscal Year Focus Document Type Policies Net cash provided (used) by operating activities Net cash provided (used) by operating activities Increase in accounts payable and accrued expenses Weighted average shares outstanding Common Class A Supplemental Cash Flow Information: Cash Flows from Financing Activities Taxes Loss from operations before income taxes Loss from operations before income taxes Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding Total current assets Total current assets Document Fiscal Period Focus Entity Registrant Name Net cash provided by financing activities Net cash provided by financing activities Adjustment to reconcile net loss to cash provided (used) by operating activities: CURRENT ASSETS Current Fiscal Year End Date Net loss per share Revenues Common stock authorized Total stockholders' deficit Total stockholders' deficit Entity Central Index Key Amendment Flag Significant Accounting Policies Notes CURRENT LIABILITIES Entity Common Stock, Shares Outstanding Net cash provided by investing activities Net cash provided by investing activities Statement of Financial Position Cash paid for income taxes Total liabilities Total liabilities Class of Stock Increase (decrease) in cash Total expenses Total expenses Accounts payable - related party Entity Current Reporting Status Document Period End Date Statement {1} Statement Going Concern Organization, Consolidation and Presentation Cash paid for interest Net loss Net loss STOCKHOLDERS' DEFICIT Accounts payable Total assets Total assets Cash and cash equivalents at end of period Cash and cash equivalents at end of period Expenses Common stock par value Entity Voluntary Filers Non-Cash Investing and Financing Activities Common stock issued ASSETS Total liabilities and stockholders' deficit Total liabilities and stockholders' deficit Entity Well-known Seasoned Issuer Class of Stock {1} Class of Stock Statement Income Statement Deficit accumulated during the development stage Deficit accumulated during the development stage Entity Public Float Document and Entity Information Subsequent Events Cash Flows from Investing Activities Common stock issued for services rendered Statement of Cash Flows Additional paid-in capital Cash {1} Cash Cash and cash equivalents at beginning of period Common stock issued for cash Entity Filer Category General and administrative LIABILITIES AND STOCKHOLDERS' DEFICIT EX-101.DEF 8 cncl-20120930_def.xml XBRL TAXONOMY DEFINITION LINKBASE DOCUMENT EX-101.CAL 9 cncl-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 10 cncl-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000040 - Statement - Cancer Capital Corp. (Development Stage Company) Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000001 - Document - Dimensions link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Cancer Capital Corp. (A Development Stage Company) Condensed Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Cancer Capital Corp. (A Development Stage Company) Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Cancer Capital Corp. (A Development Stage Company) Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Organization, Consolidation and Presentation (Policies) link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Organization, Consolidation and Presentation link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Cancer Capital Corp. (Development Stage Company) Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 12 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]A-&0U8F0Q,5\P.#8V7S0V9#1?.3DR95\Y8V%D M-F%C-F)D9C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-A;F-E#I7;W)K#I7 M;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]# M;VYS;VQI9&%T:6]N7V%N9#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-&0U8F0Q M,5\P.#8V7S0V9#1?.3DR95\Y8V%D-F%C-F)D9C<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO831D-6)D,3%?,#@V-E\T-F0T7SDY,F5?.6-A9#9A M8S9B9&8W+U=O'0O:'1M;#L@8VAA2!) M;F9O2!296=I'0^4V5P(#,P+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P M,3$S,#@X.3QS<&%N/CPO'0^+2TQ,BTS,3QS<&%N/CPO2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO'0^665S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^3F\\2!796QL+6MN;W=N(%-E87-O;F5D($ES'0^3F\\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA MF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]A-&0U8F0Q,5\P.#8V7S0V9#1?.3DR95\Y8V%D-F%C-F)D9C<-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO831D-6)D,3%?,#@V-E\T-F0T M7SDY,F5?.6-A9#9A8S9B9&8W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-&0U8F0Q M,5\P.#8V7S0V9#1?.3DR95\Y8V%D-F%C-F)D9C<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO831D-6)D,3%?,#@V-E\T-F0T7SDY,F5?.6-A9#9A M8S9B9&8W+U=O'0O:'1M;#L@8VAA2D@0V]N9&5N2!O<&5R871I;F<@86-T:79I=&EE'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!F:6YA;F-I;F<@86-T:79I=&EE M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^(#QP('-T>6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA=71O6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UA=71O6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM M8F]T=&]M.BXP,#`Q<'0[=&5X="UA=71O2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L M97,@:&%V92!B965N(&-O;F1E;G-E9"!O'0M875T M;W-P86-E.FYO;F4[/B9N8G-P.SPO<#X@(#QP('-T>6QE/3-$;6%R9VEN.C!I M;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA=71O'0M875T;W-P86-E M.FYO;F4[/B9N8G-P.SPO<#X@/'`@65A2!A9&IU'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+65G>"TM M/CQP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UA=71O'0M875T;W-P86-E.FYO;F4[;6%R9VEN+6QE9G0Z-30N M,35P=#MT97AT+6%L:6=N.FIU'0M875T;W-P M86-E.FYO;F4[;6%R9VEN+6QE9G0Z-30N,35P=#MT97AT+6%L:6=N.FIU7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/"$M+65G>"TM M/CQP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0[ M=&5X="UA=71O'0M86QI9VXZ:G5S=&EF>3MT97AT M+6EN9&5N=#HM+C'0M875T;W-P86-E.FYO;F4[ M;6%R9VEN+6QE9G0Z-34N,'!T/B9N8G-P.SPO<#X@/'`@6EN9R!U;F%U9&ET960@8V]N9&5N2!T:&4@0V]M<&%N>2!P M=7)S=6%N="!T;R!T:&4@&-H86YG92!#;VUM:7-S:6]N+B8C,38P.R!#97)T M86EN(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T92!D:7-C;&]S=7)E2!I;F-L=61E9"!I;B!F:6YA;F-I86P@'0M875T;W-P86-E.FYO;F4^3D]412`R("8C M,34P.R!';VEN9R!#;VYC97)N/"]P/B`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htm IDEA: XBRL DOCUMENT

Organization, Consolidation and Presentation (Policies)	9 Months Ended
Organization, Consolidation and Presentation (Policies)	Sep. 30, 2012
Policies
Significant Accounting Policies	NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2011 Annual Report on Form 10-K. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for year ending December 31, 2012.
Going Concern	NOTE 2 – Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References+ Details

XML 14 R2.htm IDEA: XBRL DOCUMENT

Cancer Capital Corp. (A Development Stage Company) Condensed Balance Sheets (Unaudited) (USD $)	Sep. 30, 2012	Dec. 31, 2011
CURRENT ASSETS
Cash	$ 2,705	$ 161
Total current assets	2,705	161
Total assets	2,705	161
CURRENT LIABILITIES
Accounts payable - related party	43,725	28,250
Accounts payable	54,306	44,156
Total current liabilities	98,031	72,406
Total liabilities	98,031	72,406
STOCKHOLDERS' DEFICIT
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding	6,150	6,150
Additional paid-in capital	47,050	47,050
Deficit accumulated during the development stage	(148,526)	(125,445)
Total stockholders' deficit	(95,326)	(72,245)
Total liabilities and stockholders' deficit	$ 2,705	$ 161

XML 15 R6.htm IDEA: XBRL DOCUMENT

Organization, Consolidation and Presentation

9 Months Ended

Sep. 30, 2012

Notes

Organization, Consolidation and Presentation

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION

NOTE 2 – Going Concern

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

ZIP 16 0001548123-12-000319-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001548123-12-000319-xbrl.zip M4$L#!!0````(`%LP74$G!QF5UPT``.=C```1`!P`8VYC;"TR,#$R,#DS,"YX M;6Q55`D``TY4CE!.5(Y0=7@+``$$)0X```0Y`0``[5UM;^,V$OZ\!]Q_8''` MI@=$MF3'29QD6WB=I#!VFZ1QVMY^.C`2;;.52)6DG+B__H:49$NRK5A^B7-` M^J&Q+7+FF>&\2J3VXL?GP$=C(B3E[-.!4[,/$&$N]R@;?CJ@DENGIZVVY1S\ M^,,__W'QG66A.\&]R"4>>IR@J\N?.O&#,]H,N#,%)$ MH!YC?(P5<)"'\,6M'<*U<"+H<*30]]U_HX9MGUH-VVG4T-/34XUX0RP,V9K+ M`V19FO?SH_`1@&7R3'_TZ*>#D5+A6;VNO]:X&-:!S'$]OG@0#YV.T62SXYIU MRJ32.).19Y&TAAB'TQD#+!_-Z.0"S'(;4__/SU[X[(@&VB@(,J#^=U;WI?M6`&W:[:1]DU$8K M:,0C!1U+XM:&?%R'"PNT\3RGC@2WTVZWZ^9J.A3LZJCAG)1AB4<E=`?8ER0FF9LT)77%%%63>S*D4@G,U`T. MRI%V.S?=JWO4[=SU'CI?4??V_BZFOXA2@4T7N`OL]YA'GK^022D?&PS::=JG MI^TL^0*%*?UN)(06C4H7^]\(%JLHW;)`Z4TGIK^,0D&$:^H3T87?AUR4"]`/ ML`]CT3T)N5`0,DW,PVR2E2='KJBM&-%T?E]A%DOH3#G9K,UNX9?RB70 MCI9WL<+L)=1C1WR9_B_-1=0SLPW])&VI'&&H2=W1`NZ&0G')R8@[,S#NT3^\A95X:?"",0 MICK,ZW@!928B*CHF5\\A89)47N[CYG%[QO(%ZMM#LL`^G*.6\^I(R@VJ`5EB M'YC*3+#5;K9>'U*IS3I'IZW&\7J@NEPJ"2.3:]7C5=Z`B^0VX/6BB6Z-5R4C MW"+7U

F#)/L_*N]M9E*75@ MJ^C!VY4&KB>AX#.DF`%5FU2W2TANSK:\]MT1VY4KXYWQ7[%NWA7_5:OJ5?C? M$#4SW$V318[8NFQ>#NC+V5QAP<#E)+2*_1$6Y#.6%5.@]-*YP-:NV1EU+B2^ M*7MGG^R7>])KXUCF41OA^)WH^]_$ZXPA`@_)310\$G$[,*/E;:3TS5A]&[ZR ME<04H"!W6K:=Q52)XZZP.O\W6)?:W]L&O<18=P!ZY;!9K8C<0IRN5.AM@U^U M8FPY1_A9$"S))8G_]EC'=7G$E+S#$_SH$]W+NZZ(B/>5XD?J4T4WZFE;QXU\ MS;L&^YU+4+:81Z=O7X!2ZVB?VDUGJQ*`>76Q'-T)/J8>\3Y/?I7$Z[&DU&?# MCJOH>&/#.3K*&?2*''<"M-39'?C]K2`M#Q/-9J/=VA74'AOK;FX[J_^R0A>P MVPG*%9N=_:)OGY_IA_BW@RX/`L[ZBKM_;F6A7^2R34PK M+NMK8BI=Q.9QKJ:JAFO)LE]3!O->S6,7L-L)RLT\]I505EGL-9'J.9#+]9^K MOR(ZQC[12=X\1BX6`=O*TU5X[@ALA5R]?[2E9M`XL5L[`]L!FQ)B`N;S&_:C M4I17SCPTVSYY"5J!PW8Q]8SFROQ[/5#K:FC!;;O3=D%%KP!CP4W*>2M:$49EW*:/N?8H@)S--?G5_4._H;\*M^Q M7\1O6N68^@8\^W>P7`PV?,U%GX@Q=8F\%5T?TV`[94PECKO"NNI*O0&LY0_\ M3QKV5O#>BB%F]&_S2+'+F>0^]`?T7*BD'D"LS[XNV*RQ"[Y(QQ1L[CJ1^'ZOSF M]N$*.!H62F M#3A7C"NH/J8>)!'30WQ_`J-=/X+.!#XLEFDJ"0S06A&>=G[T1-4(#>,]9$`& MKI!0:PA/W1%F`G$::@%GBIEID`O$`ZK48M(R+M5-#>H&R4@XBP:@ZH-8`+Z%AHZ]K15Q*-B]@.?N/J+[VH^-S MD"'QOH7TM(#:O(WH@H`@69.F,`(Z*Z*?6Z&F`3<(7,% MR+&M+UD]3V^F`F`9^4!)KYS&R"@C*(#D,I*(,,VJKZT_9F(;)HUXT4%]Z<)3 MXVT>)"V]S3+U\90TX`;-D.<0S$R+"IPF!`M-7B,HRM"H9<+D]E/9PFB\HXS9 M0(G.6Z#SGWA\4@+B@&#;SP1[R#='-:=5->&LFEPPE&*!GI"ZX33//%$(5&Z\ MDPN(@YN@H5&M&ZLV:^>2M.(\;3\/1^ M6!9A3_OY[.;<3!,IU-0Q0RP5DD0_K?:-_R0!T$0MCX3$%#TH"ODTVVGM\9FJ M9E`+*H((-P`,'$@*3.&;C![UXV^EE\GCT:-"^)%'\3+$S]XFJ9.GVLTR>GE- M%EJ!QTU026(;]1&OW0WD6A&] M84'>#K)\MM-6:%&_LRPR?+8L$V>V$E+>FXSW)N.]R7AO,MZ;C/>]*WKN2]ZYDCUW)++B5Q:3">0=Z)H,@0]&]2^@RR MJ*MTMWK#CO];"*C(8#M`G-W","^X6$L7G/\B%:S%O0^1"@I#<.:K ML8X2;RCW-[.Y?X83Q4#WGYK?6IF0S=-D#/ZOXX!)18GBB%'<+.H_8M]T8=!/ M$84\TQR,A.DW3&\1_[`DV3Q!!0[9P)AJFK<]`GT!%!V9;D%W'J8ZCAN>!(*Y M^L0CWXL3-H:DHEL*8$%!"-=4ZLM8+TP92^UXVSNY5MH@],I[N0K)PFP7.'8V M@=0Q]5WRZJ(-%9*CM2Z7<@%?8K$5"2K3705SGFC^',D]\;4+0U;7I>VZBW'4 M/,F>OUF%QY9!S>FA<=IHV=N#5%DEK:.F?;R4__JLY@0].G):*S+*'!5:=Z4+ MYY3F*6[$<$ZXD\915HNKL]NB8.NQJ"#*LE)MO4RA2[2%]=F"I%")UYQ$%3AU M/&BUH*O%OMXSV&-='%*E&]>J@09B9M:K%Y/=G/6\EU5G?`F%B,]#74]`OS0D M5_J.9BBHW@$^H"[5M\^B(#*!Z#+2-XJ+,RJKIWC$=',(KRK1?#+3!Q=:.Y/' M&.N(^QX14A7-%RTO MD=\BEO)"9R4@F?=E%KO6S`GWT@,-3L.Q&ZVRQG@U)@9/0AE1;[[[A>L?+HBA M8SY_N*#ZUB$=4"*0>0LNR;TX-WTK;[?W)?]*U=FTF&8]0_0B-`=3$@:`32CS M)M3X);7ZS;X7]=FO\2B2O"TU^R);,GN#*C"8$;VH)R+.B1O;UCZDC-]OK'+X MT]^JX'?VC=Y)7VI;'?VWO6F_:&,G.[2Q^"TC>Y?264%*9WTI"ZV0Y.XR3^Y$Q$V?L]>-,>OYOGQ),UVC=.+__/.6LGZ?2 M@F7OF1;,2-\A6DT"75T9^&EU988'!.NG=#](\^-%/?UNINLI^;FF2,Q-3/XY M@3.X\O+L[-,P0\6C^F!W(IL>=Q,%^E$CCQ6Q`I\/":?"1$/LDC`>4+:(W`)Y M4TK%65!^3E%.I;HP_VX#?/@?4$L#!!0````(`%LP74%&MN?N'@4``-\O```5 M`!P`8VYC;"TR,#$R,#DS,%]C86PN>&UL550)``-.5(Y03E2.4'5X"P`!!"4. M```$.0$``-U:;6_B.!#^W)7V/^2Z'[B3&@*M5FJK2C?AO@")Q^-GYAF/[3$W7\8A=88@).&L4:E7:Q4' M&.8!8?U&A4CN7EY^OG+KE2^_?_QP\XOK.AW!@QA#X'0GSOW=U^:3C(D"1_*> M&B$!9TXS&")F!'P>1K$"X;08XT.D]`CR3#_@ZIENBR:"]`?*^=7_S3FOU2[= M\UK]O.J,1J,J!'TD$K55S$/'=U*MC&62`]@B=#^-_\]N>\4SMZJ*6D3%: M=C3_59>9`^I75U=>TIJ5UNH"-1?/:O_L31M7I,D:.'.G:B)/IDP*3N$)>H[Y M?GEJY1OLF5:/!.*[;[H+'T5$(>IS$37O8`B41R$P]:Q0'TRT(3:Y1=2(/@\` ME'QA*`YT&`6G3F+@M9I$T#B5)(PHI.\&`GJ-4\PP==-Q#2&?#C&LMS`8(XIC MF@116S\O`8*Q`A8L8!JSW]LC!MD,&N4X"Z="3;!S4$B`#%+]B,P67CZ4)#C?20'31:8K_M_8S)$5(.63>4C(29Z'?H+ MT1@LA&S7MQQ$K816EJ\M75!N'ML$=0DEBH#4MCPKCG\,.-40I;%)32P4;NQ6 MO#F;D1<>8MLZ/QMU2Q8>36RMS]`Y@B6B9@,+1Y*PFQCS6.>G#IJ@+K6EYE6I M$M&P)A._LNVHJ'@"[50(.DALGBE;=3U*TBQ>R&?RO"1,;KU>;E@ACV7QR9,J M-T/-0)^<$F@=1((6FYV];-/+(ETT5]NQ8[6UW.E0'WE#SA(3UYX:5L6.@Y37 MUI5[PJP6).Z9`A$)(N$.>@03I?-V',9)LKZ+A3[GK/:P\'<`Q=!6\?:$6,P, M_P:JQ3`/H-#3T.=,$1;KZ;)PY2WTN("IW)]H#/)._Y"* M8(M9;]%8=/+)I2V;=][DKG)O$9[T_&*QM:8S;RZ:HP-$;);1A=GEIN(9A`21J0RU@[A?AP!D[8-P:9>_S,R-SIIBWVA6R#)-\:07:S5\E)W\EU%MLI>YO]D,8BQB"S7>W>RH[\G#8TX/E+C.^ MK0AQ?"RNV+M%?:]8:WV-`4*_:?SGD*BJ;ZG:9SKJ]V2>+6 M@L"LP7R8/W_K-_\!4$L#!!0````(`%LP74';):99/0H``&F/```5`!P`8VYC M;"TR,#$R,#DS,%]D968N>&UL550)``-.5(Y03E2.4'5X"P`!!"4.```$.0$` M`.U=77/B.!9][JF:_^#M>6"GJ@DAV?7R;8F4'&$267C?;1<<.! MQ*4>(J/+!N*T^?'CV7FSW?CY/]]_]^D?S:;39]3S7>@Y@U?G^NJ7S@/WD8`. MIT/Q#!C\X'2\&2#*H$LG4U]`YO0(H3,@9`W\@WSC'GV0GTU?&1J-A?//[H_. MR?'QQ^;)/ST^.8C2IE3?=7;ID3T#X_/V\%G\:M97&>6)C'2S]KA1^FK%$.G`6I M4LAWH9*`N8QB^`"'SOSEEX?>:GV(B):')JVY30M@_-X)P%Z(URF\?,_19(IA M=&W,X%"+(P*NF#]3G/^@2FN5QC260)CK#V!37H5$]:0*,6:57A[SHJRF!X?` MQZ)"Q*ME5XJ73@"JDN"5HBM`&Q34G,#)`+(JH2;*C>&,0*81)L)'*\"&//;M M*G*9%X-SB8N;41$!BE0),1A2;T20BI.W\FVB:/@B(/&@%Q6NL*P!4]4QKP13 M-UYR`ZO03%DCCKH15V@(^"#@U.?-$0!355.[!;'@T17E7[MYW)['XA_FE[\] M"B"@Q""Z&'!^/WP4U/VC\X)X5!D&`X@O&\7VK?TX$,=Q%30>#?(,PSCDI;`= ME@0OFWQ4Y+SU)[&;=.:H@"&C$Q,R(P`T%[_CC1QBPMR*(="%'$B>,=18C$75]I6_TOT.\:R*0>.V1(663 M(.?>>(PR*7N+HY=)]7L>UY[``,.BP2PTVE,'W,X07&UWS$C1"R)H@O=XA\QQ MMWZQ\Y!\')*/0_)Q2#ZJ2S[V./[(G`#VY,O"@6=I6`HRA^[1B,Y:'D0A6ODB M#5)>^A;F%`]PA+A@@(@[,$F/Z%JSO382/;.JD>A=VU(3,>4[2N>>9+$9/"<^ MMIS?I"O9O)[LFM<^9(C*3-F[DO!S"$[:U83IE'/9E)_NBO*.A.0I6#<8C#*H M3GYN.<4I9[*I_=>NJ`U#5U?"80#WY-3QY5?XJ@W+:3O+J=8XETWYV:XH[_J, M*?D1=P'^'P1,'T.TII83KWQX!!?N\+M?&G-I/U;3_O M)LOU,'$[6YE_[U:9&X0AZTIW1I3IPU#2JA;CW-_9=VBV+X6&FB=U6BQ\SGJ,E&XD5>R>H#.TG+^M0YJF-_Y M+#8$%D[WS+B/V]:*_823&OYW-J4-.V;?'V#DWF`*A#;RQ&TLYSO#*0W/Z?EM MM-KUM MW738''*'^5)3R7Z?J,$!;R>XO``&%)&.2R/P;+TV.*)2JN^J5X M+1@LC&^O@4;F5&QI1[82%%5SB`>( M91/U^H#%X.NBGLFMMJAHD`N846&[@F9BU5@7NP>O_"Z386B+$!6$.;N5*9:D M9LG!UHX-E5D*6C-OLS53RV@WR<7A=9.R?<[UER<^L&B?3&P#41D$T9XO!*4NPB(3,0?^(' MZ>"5SQ`9I>_0J%A!P342O`H:K9O1KE)@/)+5;`2SL&,6I:<;+@;MNU-5L0AD M>H#YL*=>^9YZ]CYQ'Z@IT!@*Y`*#I_Z4W%Q8@\X+4O`]9<.Z\>!:BO;,&X=N(`.OF*"O?#>CX8DP9^@MZQ7*MW%$OF58= MMBX=6D$;G.`UEF9N74=9(D?-I@>'G&?CG*?HC-S"&WX_O)]"%CXGL_KSA&5Q M[##W*0OUD/^\O?SG0;8)XFOW'!8?UR`6+UVQ+EV9]R8RNGZ9JJY6=*!3;U\# M'7*12IL:W&M"OVWKBMU*1=J MH2GR3IM3ILSVJHEA,TMFEFD_K9.B1UPZ@;>4\QOIK4PC9*OS9<-;Y@Z?X9`R M&-H]@1?(K^0++I"K4:U,B36(C*4(LV[#88%RWD0_RT8^1+HA36==&]DR'+7N M5,,=%,LVIA$B:5,#^E-.;>EQ*)N3?@T8D9V81\MEGP'7!KALVQJ(H'%R2\]' MV5R,KU#]^@7T.C,94D?PSE>.WP]7'B"2)])Z9=1`O#5),7NTRF'M:GO?@8VO MQ*AO_-Q@^KR/[\(6X+!@W\X4ZF'MZNVM764R` M.ZZ<8X4'$_*76S8HJ`91?Q-ZK)MCUBRCW;Q)KIWQ[O6$Z/]]+H)@^T0?H!Q9 M781A`O43K:9K;J6J-]!$MB.!=>NS:CM5I0+1@\F)]Q4P]6&`3J,&[XOT=27ZQ2ZZBNRWSH%7]K9L/"WD(S MV)!&&U>U#.DHG=^]K;S.PH"N`=\C,[7,73YGSRNHOMKFTF-=_#9WHK2V5L9I M@\:\F>863@4TX&\0D1E(!?TYKZ#Z]N=<>JP;?R5Z%T(OV+1^7"XC$"\CH[U"W,64^PP6A+S2Q=8@%I:GSO#7 M8@YGIXQ_R'Y!\CT;`8+^"GIHEQ).,?+"[DJ\OHR/JC>KMQO_K/WZ-6WO_-,& M8+;)_:,_X/!/7]9U/5/Y77F.5TK&D]VUVT6--K7?!:@\ M3>;7U9^!G+S+*W\#4$L#!!0````(`%LP74%29,/$`!```.7&```5`!P`8VYC M;"TR,#$R,#DS,%]L86(N>&UL550)``-.5(Y03E2.4'5X"P`!!"4.```$.0$` M`-5=7W/;-A)_;F?Z'7#IS;F=B2P[F7;J-&E'D>VGQR=' M`)&(QIA,WQQA3GL__/#=6>_TZ.>?OOKR]=]Z/7##:+R(4`S&3^#B_-W@EB]P MB@"GD_039.@Y&,1+2&2#(9W-%REB8$0(7<)4<.#/Q7^BX^?B=_,GAJF+8_#ITZ=C%$\A4V2/(SH#O9[DG6#R\97\:PPY`D)JPM\\ M>TC3^:M^7W9Z'+/DF+)I7Q![V<\;/OOJRR^^4(U?/7*\U>'3R[SY:?]?OU[= M10]H!GN8\%2*GW7D^!57SZ]HI!2P8`FT+>3_>GFSGGS4.WW1>WEZ_,CC@J`3 MG*S9#-\/K_K2,B=G+T\*;225'=6O=%D9X/3L[*RO?EML+R7 MI=:X09RU4<5`?O&:T03=H@E0/%^E3W/TYAG'LWF"GJV>/3`TJ2>7,-:7_?L$ M36&*8FG%,VG%T^^E%;]>/;Z"8Y0\`[+EA]N15K*S+5I9IWY;,MX@AFE\0?83 MMM2[9:GO4LA2![D+_5N3_%Y,>1">1C17/!>U,( MYW)^.^VC).7Y$[D6G/9.3E=SX]>KQW^\1^D0\@>Q!"VQD/KMTP>.XA&YGB,F M9F"371<%;KMV(]#[<'?TD68++A'[B8,+$8KIF!S;\7OU'+`( M4!8CMMH<%)6&+,H?B!\-4JY:]",J%H)YVLL%5MVE:$ZCD\M%G6W>[P;:5QB. M<:)$&2X80T0'W9J&SM#4,W>!GIJ(0)01!,F&1Q/>VA4]7<^5ON3OXGW1VZ#\ M/IC`LRO>.8J.IW39CQ'.H"Y^*"-!VB7D$DW\CR"[%$UX:UZ:6 M>V/<@KT+R'/2(*,-)'&@J(>"$@L#Y#"Q'H!#X^1>D&T`A_JU%T04&7F!@208 MXL@7%:T;[JI)VUO[;FB"HZ=[L1E]*[A\-.S==*V=5T&#&"[P4*0#7#D,*I>7 M#RO3A^@..+L!;6[_?0!.<`.1W/K/5_S`-PO![UL9M:-K%P!:N0!A:-JX5?.I M;M@>C[NGT]7;.B(10Y"C(\/`P[F:Z,MY]`*`][/^. MY%D'B@=+\3I.T?O%;(S8]>3N`0K,72]2&1Z71RYO(<>1!O*[T7!&^EXBNP`\ M9PA@QA%PQ0K0#:_0(+V7C@,13US MI\BHH@H463`(#5IZG;S!$EO$B9R,R+#SB,RH6RFSDX-?IUM M;V(D)))&'$Z0F0H=R(2V$ M]WF"M&;W^9T@65C*TJ^R'N=6_2LZ0_?P\2)S`-XB@B98AU]=:Q\>4I,83@=* M\#$\J!GTK?%;S'9O&S17E/-+H=60DA23A8#U*FY`"7^+Q.2-UF(C?BY^X*G6 M37&AZ`E\3NJX`%0RSB9)NF8(QHJC<-LE2Y":,!RHRHWA-Q]Z=_?N.MFN_OWV M`/^V?;N[E$8??X/)H@PV;3-/?EV5L0>OCDNBS\'?CT].3L$<,K"4#'X$+TZ> MGYRH/WEX`2[2!\KP7RC^$7S__/2[K5]BSF5(38;7`@Y#Z.Q8[RGJ1K`]P`TX M1ZDAS66[C3/4:EGZ2VZ!BKS/:7UO@7=(:3%+W06::S4O0[D!'NWDL&1YK'99 M+,6V'O-8:D3PF>'OWU,_-A(.P M'\/!G=W%_=WP2&V2>U&-\X/9FRWYBNFFS3W"Q*?P[1N M>ZYMZK1%-PG@!)&5AU^\E"#(`TD_%,#8V*"X8;<;A?:FF`O(B)CSN'`J5:Y. M4^Y6?5OG*:91!-==MUH_QQ4)#08V5ZN5IQL+\[>'F%BT166A=N?6OG=%1 M9N0"B)Q6:#`HZU@>^7IK=G*VDB7T#=;'#>9CEDH/GRPBEKR@#11H(VJ&@PZA\-9K>:/A#86,P0R169SP)G-9@8OOW3EBH9>44 MO\H)`DDQI)&O5;4XX@UF;6\-E!MY?CVY$>,F,XY5AC&)[_"48#'30I*N+@6) MS7]^!7=]>U6S6CJ1=%Y7?2CDE+"^X00VK$"H]Y=]F*N\QOD#0'OOP3GFD?#7 M%PS9WJ)OZN&,8@MQG*(3-`T/BA8ZEY%F/09=EB$RX*BAPP'*$ATBC'XU&KP= M78WN1Q?!Q=+-!C`7^&DWJK[:!Y:]Y<(U1OVNO:F3CRV\A5`^]O-9#.0N2T#- M.('K\))'=S-,S5[?>K@ZSZ,9D:5,L-X_CZ:.P*'R:!J$]9Y'@W->[>;1.*JX M>Q[-KGH&E$?38"O+/!HC>-L,6<)4W0V]GJRR>V!R0SFVN1ULT]5#6-->0"=1:M7"!>M\G5550:XG M:I<^>,0Z#.O;^UM1=:(XS7JJ=HM80A75T+!B5%V[5#8/0XO9"V)5&9!8_B-/ M^Y8PDY;Z#@$XGY>62ESW`,E[R>G\:3-;$/G:I M9,7O/'('#N=G+&_1G#(92)+[E-IKSXW-?83P&P7Q$;Q?Y8E`.?7-^_;LS7LO9R6WYU33[$VQ6-RM?=DF\P?`?.ZQ4F M:"1^-'JMFX;^W-4*_L]O$JN+N.GZNV9-,H>":+/.6G]:`Y`VPXC" M78K%-%R3\J&-*S9T\1!H-`OD@OAW5"Z>0SF:++CC#!OEJU$]V^%H#U77;`H) M_DNEJ`E3UJ\$W^CAFC'9NAC.Z._*<"YO5%%F^?W<@M2J M/EE1[M!>N*[L77Z)NT5JF^>:8FE'/&T\U"PT\7"B667H\S@SHQX:K.NTKIYC MZNS<:EK4IH2#!@_;;7PD-U59^KB1[#D]:3\AC1E()DD[2C"J:EN30Z2#09-U;F;.WG)K#`+Y;SGEYZL2M]&&UX`I@#)"MP3 M68X&T\9Z$MWI-<^#Y[KWP8^"7>6.F(U4ERUB"\D6@V9YL;K\:-^PM]2W=P]# MF41Q.M$,-`/#J'0E:&,W`)W4]+F![)JI$%&L0)T7F-)-TA8]?=;X,8GGK=;/ M^@L+H:%M!V,TE/RQ&ZS#)F'\1A.Q4X;LZ1(GPJ&J.3ZO;^R^4$S]N+G^1N*:@9"H=BW?0Y?Q/-EOKI-GC]@=%B8;Z0^]6->N+=:^R_(MRV&MP4Z M^Y!1<*!LUMY8A*]N%-J.&ED5E_9=5=IK#?6`RTC;U8_N>BXIW/B21\.V=1F- MW7Q>)VP4S.L=0[4DME/#T:=^N]U+=%"RXVN+C89JN,MH`='#.D"_HR3YA=!/ MY`Y!3@F*U>Q?_@Z]N;T'A\@@B@?'2'+H?90L0,X#9$Q"@9:U-:JNDM7(M+@5 M+-RV/*ID;\T^GM?!][AIZ/?-QUT-QFX[7HG:UD,KHNNM:?Z)UHQ'"]DR\HGP:+% MH'I]%13#$+189A0M44+G4A0ATQ1=R.3&.">U;#TX))E5($B M&PK8&G6N.EY:.]M`(")1(H?YQ(3"B;P8:2?M;= M]H;"KH)YN0@L(T(KJ!18A8*474V2@V>_P6K1O5F,.?IS(:2[6,HL(]-E-7U[ M=Z?')(J3_[,F#C+JH0#+6ON*2V0W$B%6#S8X3GL0:K&:L-<:ZO(P7![_KFX?\A4OP!`12`WO%'TO2U4B#?N/;B?UH_.\$]-;S$875=.M;_*8^Y[H%JIA[K8 MX_L(TK?PS:>2AGJNG4N?71L24RI+FW30WCX:HRDF\A/98=]!LK:97>':0&XD M"?\A0BCFET+?S3:LD.RHF2?,_9SG"&O1#K'Q#K&*LK5!R@C<<;`.&Y-75Q2& M8O\UI4S_&=WM5A[B\K5L/43F%5V0$PX%,@:]J]'Y!GNW-QF]0P0QF(C)SA.1I5@N8%JQ4&LDW&(2"J)V-$9Y"MIID,+)GK;_ M`&5S]X-G4_MT_`L?I02#]^?@\ZD3LZN5=DTYWA[/HO97XB?Q+'\D_AI#CL23 M_P-02P,$%`````@`6S!=0=?*I^+A"@``@YP``!4`'`!C;F-L+3(P,3(P.3,P M7W!R92YX;6Q55`D``TY4CE!.5(Y0=7@+``$$)0X```0Y`0``[5U;<^(X%G[N MJ9K_P/8\L%O5A)!L[R2ISDX1DDQ1DTFH)#V]^]0E;`':%A(MR23,KQ_)QF!L MRY:Y66;STJ'-D73.]QT='5TL/OWR.L:U*60<47)9;QT=UVN0.-1%9'A91YPV MSLX^GC=:]5_^_>,/G_[6:-1ZC+J>`]U:?U:[N?ZU_<@])&"-TX%X`0Q^J+7= M*2!*H$/'$T]`5NL20J=`R!;X!_D?Y^B#_&XR8V@X$K6_=_Y1.SD^/FN<'+=. MCFHO+R]'T!T"YE=[Y-!QK=%0;6-$OEVH?_J`PYK4FO#+]R,A)A?-IBKTVF?X MB+)A4U9VV@P%W__XP[MWOO#%*TM1HG31.6T>OW(TH.D!XT4SGOG/75,@ M1V14+07-3Q29`]`Z/S]O^M]&I65UKEB(1VO_V`R^C$FC#'46H$HBWP5,,HKA M(QS4U-_/C]UT@YOJVR9RV==KZGAC2$3XMTW<&R*0F'7)@+*QS\W[FF_%A9A- MX.5[CL83#,-G(P8'E^\=XN!&6+E"_2?CNIM+U2<,Z M8&`$P43*TFQ(*'3Y0QK<9Q:]YA?IH__OHDF8!*N6?0 MQS"FO$8HJFJ4SC9;51LP)ZQ0?O2YK&N]?"[1G,@P2$3#&2'LAJ4'C(X+0!DJ M0;46U#PN=:$350S@>HTR%[(@@)?-0P<#SA\&3X(ZW]JOB.=1DI`OB9ULATKE M(FFJ=;1$5;RF8X"(AH\405N(T'E4E),T._5DU*0Y`\@8=.\"%+3J^KK*+(9# M7[(T&NEX3(EO9/MW..Y#IJ,Q*5@I&E/L3*?QQ()0)X=_V)4?W6NI?@;$JW*5 MP3IF7CKHI_L"O2U5_=YZD&/FI(/[SWV!&P2PCE2'`=R5T^;7 MW^!,&Y[C_[,*6<^(B>'IW/R\7VYN$8:L(\T94J8/1JM2 M%4$_9EHZW&=[[@I!3WV$$\J$]`)EBQ>?3^6*5X0`G;'I3)SOEXD_*/8D;"QP M$ST%<;F*8)\P3S-1.MXOZE\@QK\1^D*>(."40+?+N9=8WH).TG@&MB1KL]SZS#10+)H!FZ$=E*X;_BID:!O8VS0TZ9\_K M8^3<8@KBFX#I,M8CGF*6!NG%G/=3,V&.K/[;VCO7';7Q+9.N"1(`=RB;M*_A M%&(Z48I+"X90G9,`1*;&VOM[W(' M?&M*EKP?\#"X143JA63WIAQE[*H7*EKV-H?].^OK,%'-W?5$K/N_VG*JY-YM MFW,9I'("04S(%LY2AU:=8=;UFD#!^:S;B("X;,D\I+M.DH.$B=91T0%\U":N M^G/SW4-3@*6^O"TZ@+$9(L,_`/9T8XQ962NHTOC:RA$',R0.+@#.H3'I?G9P M:=SMMGE`@LH,V`*R,EDJFYXBH]-!<7.'0!]AF"7X-0=C1V<(ML*C67*24:!DKHJZI(9!^Q.8MN-03P[4/3!3\YA'B*63 MNCW`(NKKHJ9)47MX-,AAS,"PG4,SNBK-C(6G9Y/V&`<]BZC80K`[U-0DG\ZR M>2R<8&0=E:L<587S1GLSQ12O6UU8+)H4EKE"LCP;E;D8$AVZ*-"F!Y#;)?-M*5VRH)&N%"M:DZU+'N+[@C=$0#9AB,-K.$`.$C+_\<:> MGXY>>PR18;R$AL;3HFG@=C(H%#U8YEHZ+Q:%@V\X5'P4/- M/%.3\C47P\HF=3N+8%FO&VS(=&DG9=+/?O1\1$=0(`?@G9^6,='!BA,S)HJ^ MG9IY.S7S=FKF[=2,59O&D9FBC%8/S#?7]2>-/T]=_!,"9G+EU-8D)3<[:$=Y[; MYIUO7IC''P8/$\B"Z_.V?QI\4SWVFN-NJFPYW:U+'#J&"]UR4EN==-D95'6R MV1R\WQ+8MP1V+]P]RFA%/.UVZ.)K6WC*'$B7QEC71^:1G@QO7B=J&,@[::^7 MKP03&>9:EVG^"HE4%K>)VW;'B/CW5`DTA7/5-03EE2J9IEQ_B[*5BX!UW:E# MN5!KR:%UVFE!3*QD5@Q=;75R$+=T>Z-/Z;LB019T1SF_E3C)%%EZK">==ID7 M7\$!93"0>P:OD%_+#UP@)S,S7:_&2D36C2#;?"_4,M>1]LT[QI7L6@.4/6%) M2E>(\A13=W0SVOJDW$.Q]$\-%:LRE2`@9M;.-BOW3]@-8$0&#QZNU%X!K@VM MZ;*5(%!CYHZN65N?CB]0_=P$=-M3&%GQD\TT?H4.(@#%>T?J;;Z9X[:>H@G&0W M)%BW5Z!.9JC,-?R!&.)^`4S]K`6_I>P)LBERY(R$=3!`VO&[6!T'X1T%8;/N M*@3IQ`P"]=9)\+=+8F\PJQ5]QV&>S%AR7S%=L[+#<(0U@;1QI=,0CHTSO;*9 MWW:&=U#O]6C,[I*IVG+9////JJC*?I$)D'7QW]R(C=DMF]7U'7H]U@]J/UMC M]OQ]EI=>B_=#(+PXTV?K,GU#2KX:Q9M,L(\*P.&.<)<, M*!L#DY?U#4M7@GEC*';TDVZ;++0**%$5ZH8G[?)I1*1L.HKYW.I*:-12ZQ+B MR/'A3"Y6I:I,1\Q>Z[:>0H/N*7'DQ^52"G%3LO)KQ!U,N<=@3N#;N-JR.3<> M"S<#S_"'&$M`8%N.L?4-N]:N3EPN;7A@0T#0GWZ5'4HXQ<@-L"=N+]+N;!7@\S>U2@YGAGXSLJKIGMGJ;1H]^3U.?SNR5IO MIDK[S:-:HL;]1*]$LV]1:H-Y[RJ6>>%$+U^M?I]AM_7I2!A4]I>6+%JT*SU9 MJ%723IYJ?F;:^772)75\];83?QA$X=PTU=BHRI+#1PZ7T="Q&7+6K=7\> MK(GM4$```^(0``$0`<`&-N8VPM,C`Q,C`Y,S`N>'-D550)``-.5(Y03E2. M4'5X"P`!!"4.```$.0$``.U9;6_B.!#^O"?=?_#Q):W4$`+7O8*@*XYV5Y5Z M;=7N2ONM,HD#UCEVUG:@W5]_X[Q`>,N&0K6K*WS!;\\\,Y[QQ,ET/SR%#$V( M5%3PGN76&Q8BW!,^Y:.>196PS\Y.V[9K?3C__;?N'[:-[J3P8X_X:/B,+B\^ M]>]53#5!2@1ZBB4Y07U_@KE9,!!A%&LBT17G8H(U,*@3Z'CU$YB+GB4=C34Z M&ARC9J-Q9C<;;K..IM-IG?@C+!.Q=4^$R+8-M_+&),0(U.6JPP7G<=BSQEI' M'<A9'4A1XZOI:.?(^+`(AM6$4D]*\4M`*:M9#EPN\[7?ZX?$OG9PDZL M[!'&T0P08#5,EF<3`'-=N^':+3>',,K_7:\14+0<,SW$BN3+`\IFJP]:W&#,:4.+G>".=EO!1KK3Q@X4TEB.B;W!( M5(0]LHDU%>N3N=!$H")>?20F#DPL&(VUEG0(_EU0,^:KBJYL3+;S;KO==I+9 MHDV^7N3/##IUTDD+8N%=%T-$Z22B3!?Z441Y()+.NZX1V! MI;Q7M,7#;%M; M`.+%[)7#S/8AY3OUQ#U>[5]"DR-RJR:Q_5Y`WY_ M-I"-9@*@G9*BC!49VCHZ*C"CA!IEW,=SL$(B0'-^=#33X+CK+',758H5\6_Y M>=)>SB09,ENR";5X6*MAEF)H#2@;RN-@E]BXH+!#YHZAYNXMC)5YJ.&"5RZ$ M%V<.FL/>_*ZN')#^AA,R$-R'32/^WY@9S,.8$%WIR+U48IE'F]7.7!^5G+H9 M/\H40*D&AU.W4WP44^D`J_%')J;[B9,?2"Z+E].]QLMBOC:JH$270^2\)'+V MEE!^4AXY9(_=8V#O2>,GYXI#AJARH\MN9/E_G_N77%/]?`4OXC),M"C<]:JL M+O.KVUBZ!>9-S'V4BD(%60?W4.4QH6));N4(<_H]X86GH!*,^DD'?'!7,/X. M)CQX&RQ>T%\LH\R59XDK9[*A4Q1OO@T6"!+_%BG044YR.(/;.V@7YY8Z]?U. M3GWSGJSZJ6/M=7HO'U$J2W[=KRF;[NF'[RH_R``/\5"1;S'8>#DQF[;NI*^L M*?/E7RLG>@Y'*?[-;_^.;S=W6,*Z,=$4M-[;.].BU#(7MU[U!0J>U$5-_D>' MM>L4"D[06:A&=6D8":E16K"\%EXR4U*I,ST[+]?99LAVFW;+K3\IWT)\I6Y7 M4NMSME5@7BQ-"Z6&OFWHW?>5Z)?QNV@@^,VN2A0JOELK4B@R&@5.-U&OK4I6 M84N`:PO)#F%:Y2/VO,JZ2872:G1E598KNZ91@;RT*IR29P5LA(=*2^SIGJ5E M3"R3X*R`LL>RM\!^A@%JRA@>,I*CC2H]JQHVJ8YWX,Y`A6^.;<_RX_3^8"$% MCS$`QJ;W28HXZEGI`L``00E#@``!#D!``!02P$"'@,4```` M"`!;,%U!1K;G[AX%``#?+P``%0`8```````!````I($B#@``8VYC;"TR,#$R M,#DS,%]C86PN>&UL550%``-.5(Y0=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`6S!=0=LEIED]"@``:8\``!4`&````````0```*2!CQ,``&-N8VPM,C`Q M,C`Y,S!?9&5F+GAM;%54!0`#3E2.4'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`%LP74%29,/$`!```.7&```5`!@```````$```"D@1L>``!C;F-L+3(P M,3(P.3,P7VQA8BYX;6Q55`4``TY4CE!U>`L``00E#@``!#D!``!02P$"'@,4 M````"`!;,%U!U\JGXN$*``"#G```%0`8```````!````I(%J+@``8VYC;"TR M,#$R,#DS,%]P&UL550%``-.5(Y0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`6S!=0<7JR)[5!```/B$``!$`&````````0```*2!FCD``&-N8VPM M,C`Q,C`Y,S`N>'-D550%``-.5(Y0=7@+``$$)0X```0Y`0``4$L%!@`````& -``8`&@(``+H^```````` ` end XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 18 R7.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2012

Notes

Subsequent Events

NOTE 3 – Subsequent Events

XML 19 R3.htm IDEA: XBRL DOCUMENT

Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Common stock par value	$ 0.001	$ 0.001
Common stock authorized	20,000,000	20,000,000
Common stock issued	6,150,000	6,150,000

XML 20 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012	Oct. 25, 2012
Entity Registrant Name	CANCER CAPITAL CORP
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Amendment Flag	false
Entity Central Index Key	0001130889
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		6,150,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3

XML 21 R4.htm IDEA: XBRL DOCUMENT

Cancer Capital Corp. (Development Stage Company) Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		186 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Revenues	$ 0	$ 0	$ 0	$ 0	$ 0
Expenses
General and administrative	6,369	1,451	23,081	5,935	148,526
Total expenses	6,369	1,451	23,081	5,935	148,526
Loss from operations before income taxes	(6,369)	(1,451)	(23,081)	(5,935)	(148,526)
Taxes	0	0	0	0	0
Net loss	$ (6,369)	$ (1,451)	$ (23,081)	$ (5,935)	$ (148,526)
Net loss per share	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted average shares outstanding	6,150,000	6,150,000	6,150,000	6,150,000

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

+ Details

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 22 R5.htm IDEA: XBRL DOCUMENT

Cancer Capital Corp. (A Development Stage Company) Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		186 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash Flows from Operating Activities
Net loss	$ (23,081)	$ (5,935)	$ (148,526)
Common stock issued for services rendered	0	0	17,200
Increase in accounts payable and accrued expenses	25,625	4,825	98,031
Net cash provided (used) by operating activities	2,544	(1,110)	(33,295)
Cash Flows from Investing Activities
Net cash provided by investing activities	0	0	0
Cash Flows from Financing Activities
Common stock issued for cash	0	0	36,000
Net cash provided by financing activities	0	0	36,000
Increase (decrease) in cash	2,544	(1,110)	2,705
Cash and cash equivalents at beginning of period	161	2,007	0
Cash and cash equivalents at end of period	2,705	897	2,705
Supplemental Cash Flow Information:
Cash paid for interest	0	0	0
Cash paid for income taxes	0	0	0
Non-Cash Investing and Financing Activities
Common stock issued for services rendered	$ 0	$ 0	$ 17,200

XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 11 50 1 false 0 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://CNCL/20120930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - Cancer Capital Corp. (A Development Stage Company) Condensed Balance Sheets (Unaudited) Sheet http://CNCL/20120930/role/idr_CancerCapitalCorpADevelopmentStageCompanyCondensedBalanceSheetsUnaudited Cancer Capital Corp. (A Development Stage Company) Condensed Balance Sheets (Unaudited) false false R3.htm 000030 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) Sheet http://CNCL/20120930/role/idr_CancerCapitalCorpADevelopmentStageCompanyBalanceSheetsUnauditedParenthetical Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) false false R4.htm 000040 - Statement - Cancer Capital Corp. (Development Stage Company) Condensed Statements of Operations (Unaudited) Sheet http://CNCL/20120930/role/idr_CancerCapitalCorpDevelopmentStageCompanyCondensedStatementsOfOperationsUnaudited Cancer Capital Corp. (Development Stage Company) Condensed Statements of Operations (Unaudited) false false R5.htm 000050 - Statement - Cancer Capital Corp. (A Development Stage Company) Condensed Statements of Cash Flows (Unaudited) Sheet http://CNCL/20120930/role/idr_CancerCapitalCorpADevelopmentStageCompanyCondensedStatementsOfCashFlowsUnaudited Cancer Capital Corp. (A Development Stage Company) Condensed Statements of Cash Flows (Unaudited) false false R6.htm 000060 - Disclosure - Organization, Consolidation and Presentation Sheet http://CNCL/20120930/role/idr_DisclosureOrganizationConsolidationAndPresentation Organization, Consolidation and Presentation false false R7.htm 000070 - Disclosure - Subsequent Events Sheet http://CNCL/20120930/role/idr_DisclosureSubsequentEvents Subsequent Events false false R8.htm 000080 - Disclosure - Organization, Consolidation and Presentation (Policies) Sheet http://CNCL/20120930/role/idr_DisclosureOrganizationConsolidationAndPresentationPolicies Organization, Consolidation and Presentation (Policies) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Cancer Capital Corp. (A Development Stage Company) Condensed Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Apr. 10, 1997' Process Flow-Through: 000030 - Statement - Cancer Capital Corp. (A Development Stage Company) Balance Sheets (Unaudited) (Parenthetical) Process Flow-Through: 000040 - Statement - Cancer Capital Corp. (Development Stage Company) Condensed Statements of Operations (Unaudited) Process Flow-Through: 000050 - Statement - Cancer Capital Corp. (A Development Stage Company) Condensed Statements of Cash Flows (Unaudited) cncl-20120930.xml cncl-20120930.xsd cncl-20120930_cal.xml cncl-20120930_def.xml cncl-20120930_lab.xml cncl-20120930_pre.xml true true